Journal article
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment
- Abstract:
-
OBJECTIVES: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy and resistance data for non-B subtypes are limited. Two recent trials have identified the integrase L74I mutation to be associated with integrase inhibitor treatment failure in HIV-1 non-B subtypes. We sought to define the prevalence of integrase resistance mutations, including L74I, in West Africa.
METHODS: We studied a Nigerian cohort of recipient...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Wellcome Trust
More from this funder
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- Journal of Antimicrobial Chemotherapy Journal website
- Volume:
- 75
- Issue:
- 6
- Pages:
- 1575-1579
- Publication date:
- 2020-02-27
- Acceptance date:
- 2020-01-16
- DOI:
- EISSN:
-
1460-2091
- ISSN:
-
0305-7453
- Pmid:
-
32105319
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1094655
- Local pid:
- pubs:1094655
- Deposit date:
- 2021-01-09
Terms of use
- Copyright holder:
- El Bouzidi et al.
- Copyright date:
- 2020
- Rights statement:
- © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record